• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抑制性腺苷受体调节的结构-功能分析

Structure-function analysis of inhibitory adenosine receptor regulation.

作者信息

Palmer T M, Stiles G L

机构信息

Division of Biochemistry and Molecular Biology, University of Glasgow, U.K.

出版信息

Neuropharmacology. 1997 Sep;36(9):1141-7. doi: 10.1016/s0028-3908(97)00128-7.

DOI:10.1016/s0028-3908(97)00128-7
PMID:9364469
Abstract

Pharmacological and molecular cloning studies have revealed the presence of four adenosine receptor (AR) subtypes, termed A1, A2A, A2B and A3. Given that the A1 and A3ARs can both bind adenosine and couple productively to inhibitory G-proteins, the significance of the existence of multiple inhibitory AR subtypes remains obscure, although one possibility is that these receptors are regulated in a subtype-specific manner. In this review, we summarize our investigations into the mechanisms underlying the agonist-induced desensitization of inhibitory AR function. The results of this work demonstrate that while the A1AR desensitizes slowly over a time course of several hours, the A3AR desensitizes within minutes of agonist exposure. Molecular biological studies have begun to delineate the structural requirements responsible for these differences, and will provide a basis for future experiments designed to determine whether the ability of an inhibitory AR receptor subtype to 'turn-off' at a specific rate has implications for the physiological role of that receptor.

摘要

药理学和分子克隆研究已揭示存在四种腺苷受体(AR)亚型,分别称为A1、A2A、A2B和A3。鉴于A1和A3ARs都能结合腺苷并有效地与抑制性G蛋白偶联,多种抑制性AR亚型存在的意义仍不明确,尽管一种可能性是这些受体以亚型特异性方式受到调节。在本综述中,我们总结了对抑制性AR功能激动剂诱导脱敏机制的研究。这项工作的结果表明,虽然A1AR在数小时的时间进程中缓慢脱敏,但A3AR在激动剂暴露后几分钟内就会脱敏。分子生物学研究已开始描绘造成这些差异的结构要求,并将为未来旨在确定抑制性AR受体亚型以特定速率“关闭”的能力是否对该受体的生理作用有影响的实验提供基础。

相似文献

1
Structure-function analysis of inhibitory adenosine receptor regulation.抑制性腺苷受体调节的结构-功能分析
Neuropharmacology. 1997 Sep;36(9):1141-7. doi: 10.1016/s0028-3908(97)00128-7.
2
Molecular basis for subtype-specific desensitization of inhibitory adenosine receptors. Analysis of a chimeric A1-A3 adenosine receptor.抑制性腺苷受体亚型特异性脱敏的分子基础。嵌合A1 - A3腺苷受体的分析。
J Biol Chem. 1996 Jun 21;271(25):15272-8. doi: 10.1074/jbc.271.25.15272.
3
Induction of multiple effects on adenylyl cyclase regulation by chronic activation of the human A3 adenosine receptor.通过人A3腺苷受体的慢性激活对腺苷酸环化酶调节产生多种效应。
Mol Pharmacol. 1997 Oct;52(4):632-40. doi: 10.1124/mol.52.4.632.
4
Agonist-dependent phosphorylation and desensitization of the rat A3 adenosine receptor. Evidence for a G-protein-coupled receptor kinase-mediated mechanism.
J Biol Chem. 1995 Dec 8;270(49):29607-13. doi: 10.1074/jbc.270.49.29607.
5
The role of receptor structure in determining adenosine receptor activity.受体结构在决定腺苷受体活性中的作用。
Pharmacol Ther. 2000 Feb;85(2):55-75. doi: 10.1016/s0163-7258(99)00051-0.
6
Subtype-specific regulation of receptor internalization and recycling by the carboxyl-terminal domains of the human A1 and rat A3 adenosine receptors: consequences for agonist-stimulated translocation of arrestin3.人A1和大鼠A3腺苷受体羧基末端结构域对受体内化和再循环的亚型特异性调节:对激动剂刺激的β-抑制蛋白3易位的影响
Biochemistry. 2002 Dec 17;41(50):14748-61. doi: 10.1021/bi0262911.
7
Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells.人腺苷受体亚型的比较药理学——CHO细胞中稳定转染受体的特性研究
Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):1-9. doi: 10.1007/pl00005131.
8
Subtype-specific kinetics of inhibitory adenosine receptor internalization are determined by sensitivity to phosphorylation by G protein-coupled receptor kinases.抑制性腺苷受体内化的亚型特异性动力学由对G蛋白偶联受体激酶磷酸化的敏感性决定。
Mol Pharmacol. 2000 Mar;57(3):546-52.
9
Adenosine receptor subtypes: characterization and therapeutic regulation.腺苷受体亚型:特性与治疗调控
Annu Rev Pharmacol Toxicol. 1995;35:581-606. doi: 10.1146/annurev.pa.35.040195.003053.
10
The structure and function of A1 and A2B adenosine receptors.
Life Sci. 1998;62(17-18):1519-24. doi: 10.1016/s0024-3205(98)00100-3.

引用本文的文献

1
Low Density Lipoprotein Cholesterol Decreases the Expression of Adenosine A Receptor and Lipid Rafts-Protein Flotillin-1: Insights on Cardiovascular Risk of Hypercholesterolemia.低密度脂蛋白胆固醇降低腺苷 A 受体和脂筏蛋白 flotillin-1 的表达:高胆固醇血症心血管风险的新见解。
Cells. 2024 Mar 11;13(6):488. doi: 10.3390/cells13060488.
2
Pro-inflammatory Effect of Downregulated CD73 Expression in EAE Astrocytes.EAE星形胶质细胞中CD73表达下调的促炎作用
Front Cell Neurosci. 2019 May 29;13:233. doi: 10.3389/fncel.2019.00233. eCollection 2019.
3
Pyran Template Approach to the Design of Novel A Adenosine Receptor Antagonists.
吡喃模板法用于新型A腺苷受体拮抗剂的设计。
Drug Dev Res. 1999 Dec;48(4):171-177. doi: 10.1002/(SICI)1098-2299(199912)48:4<171::AID-DDR4>3.0.CO;2-5. Epub 2000 Feb 11.
4
Tubuloglomerular feedback and renal function in mice with targeted deletion of the type 1 equilibrative nucleoside transporter.靶向敲除 1 型协同核苷转运蛋白的小鼠中的管球反馈和肾功能。
Am J Physiol Renal Physiol. 2013 Feb 15;304(4):F382-9. doi: 10.1152/ajprenal.00581.2012. Epub 2012 Dec 26.
5
Purine nucleosides: endogenous neuroprotectants in hypoxic brain.嘌呤核苷:缺氧脑内的内源性神经保护剂。
J Neurochem. 2012 May;121(3):329-42. doi: 10.1111/j.1471-4159.2012.07692.x. Epub 2012 Mar 14.
6
ATP and adenosine in the local regulation of water transport and homeostasis by the kidney.ATP和腺苷在肾脏对水转运及内环境稳态的局部调节中所起的作用
Am J Physiol Regul Integr Comp Physiol. 2009 Feb;296(2):R419-27. doi: 10.1152/ajpregu.90784.2008. Epub 2008 Nov 19.
7
GABA(B) receptor activation desensitizes postsynaptic GABA(B) and A(1) adenosine responses in rat hippocampal neurones.GABA(B)受体激活使大鼠海马神经元的突触后GABA(B)和A(1)腺苷反应脱敏。
J Physiol. 2002 Oct 15;544(2):459-67. doi: 10.1113/jphysiol.2002.023093.
8
Thyrotropin regulates adenosine A(1) receptor expression in rat thyroid FRTL-5 cells.促甲状腺激素调节大鼠甲状腺FRTL-5细胞中腺苷A(1)受体的表达。
Br J Pharmacol. 2000 May;130(2):471-7. doi: 10.1038/sj.bjp.0703325.